ZIOPHARM Oncology, Inc. logo
ZIOPHARM Oncology, Inc. ZIOP

ZIOPHARM Oncology, Inc. Balance Sheet 2011-2026 | ZIOP

Annual Balance Sheet ZIOPHARM Oncology, Inc.

2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

-110 M -77.4 M -61.7 M -70.9 M -81.1 M -141 M -42.8 M -68.2 M -73.3 M -105 M

Long Term Debt

4 M - - - - - - - - -

Total Non Current Liabilities

4 M 1.58 M 4 K 37.6 M 42.5 M 48.2 M 570 K 14.6 M 16.1 M 23.1 M

Total Current Liabilities

18.4 M 12.5 M 9.48 M 20.9 M 15.8 M 18.1 M 10.8 M 7.79 M 18.9 M 13.4 M

Total Liabilities

22.4 M 14.1 M 9.49 M 58.4 M 58.3 M 66.4 M 11.4 M 22.4 M 35 M 36.5 M

Deferred Revenue

- - - 6.39 M 6.39 M 6.86 M 1.36 M 800 K 800 K 815 K

Retained Earnings

-764 M -684 M -566 M -712 M -658 M -493 M -373 M -341 M -284 M -188 M

Total Assets

146 M 109 M 95.1 M 106 M 106 M 154 M 45.2 M 71.8 M 83.4 M 108 M

All numbers in USD currency

Balance Sheet is a fundamental financial report of ZIOPHARM Oncology, Inc., providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.5 0.45 % $ 862 M canadaCanada
ADC Therapeutics SA ADC Therapeutics SA
ADCT
$ 3.83 1.32 % $ 105 M schweizSchweiz
Agenus Agenus
AGEN
$ 3.64 9.31 % $ 108 M usaUSA
Agios Pharmaceuticals Agios Pharmaceuticals
AGIO
$ 35.08 -0.36 % $ 2.03 B usaUSA
Akebia Therapeutics Akebia Therapeutics
AKBA
$ 1.39 0.36 % $ 357 M usaUSA
Akari Therapeutics, Plc Akari Therapeutics, Plc
AKTX
$ 3.95 -11.63 % $ 266 B britainBritain
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Aldeyra Therapeutics Aldeyra Therapeutics
ALDX
$ 1.57 -5.42 % $ 94.3 M usaUSA
Aligos Therapeutics Aligos Therapeutics
ALGS
$ 8.08 1.38 % $ 79.9 M usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
$ 331.14 3.85 % $ 43.4 B usaUSA
Altimmune Altimmune
ALT
$ 3.4 1.8 % $ 300 M usaUSA
ALX Oncology Holdings ALX Oncology Holdings
ALXO
$ 1.99 0.81 % $ 107 M usaUSA
Amgen Amgen
AMGN
$ 344.03 -1.12 % $ 185 B usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
$ 12.27 -1.68 % $ 3.85 B usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
$ 14.99 1.28 % $ 220 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
ANI Pharmaceuticals ANI Pharmaceuticals
ANIP
$ 73.8 -0.55 % $ 1.43 B usaUSA
Annexon Annexon
ANNX
$ 5.56 1.0 % $ 862 M usaUSA
Annovis Bio Annovis Bio
ANVS
$ 2.56 12.28 % $ 52.6 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.88 -5.16 % $ 4.8 M chinaChina
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Aprea Therapeutics Aprea Therapeutics
APRE
$ 0.7 -1.87 % $ 4.58 M usaUSA
Aquestive Therapeutics Aquestive Therapeutics
AQST
$ 4.12 -0.24 % $ 441 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
$ 8.14 1.31 % $ 223 M israelIsrael
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Ardelyx Ardelyx
ARDX
$ 5.99 0.84 % $ 1.44 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
argenx SE argenx SE
ARGX
$ 749.99 0.48 % $ 25 B niderlandNiderland
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 24.06 1.82 % $ 3.06 B usaUSA
Arvinas Arvinas
ARVN
$ 10.87 0.14 % $ 771 M usaUSA
Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals
ARWR
$ 60.28 -1.23 % $ 8.06 B usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Assembly Biosciences Assembly Biosciences
ASMB
$ 29.51 1.72 % $ 331 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.62 1.82 % $ 8.71 B australiaAustralia